cagrisema cagrilintide semaglutide phase 3 results 2024 2025 Novo Nordisk has officially filed for FDA approval of CagriSema, a powerful new once-weekly injection that combines a GLP-1 receptor agonist with an amylin analogue, setting the stage for the next major Novo Nordisk's Cagrilintide shows promising

By the 80-week mark, roughly 65.3% of those on the 12 mg dose had crossed below a BMI of 30, the cutoff used to define obesity, Lilly said

This mechanism opens research applications that single or dual agonists dont address

In fact, the American Diabetes Association (ADA) cites that individuals with diabetes are at a higher risk of yeast infections and may be harder to treat

#emergingcreator #kindpatches #health #mood #mind Starting on my 2026 summer body Started these on 8/1

Legitimate clinical reasons exist to avoid semaglutide (for example, if you have a personal history of medullary thyroid cancer), but the desire to combine Wegovy with phentermine usually indicates that your current therapy isn't quite rightnot that adding a stimulant is the answer

doi: 10.1186/s13054-025-05516-2 58